Brokers Issue Forecasts for Inari Medical FY2026 Earnings

Inari Medical, Inc. (NASDAQ:NARI - Free Report) - Research analysts at Leerink Partnrs cut their FY2026 earnings estimates for Inari Medical in a research report issued to clients and investors on Monday, October 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.19 per share for the year, down from their previous estimate of $0.21. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Inari Medical's current full-year earnings is ($0.75) per share. Leerink Partnrs also issued estimates for Inari Medical's FY2027 earnings at $0.56 EPS and FY2028 earnings at $1.00 EPS.

NARI has been the subject of several other research reports. Leerink Partners started coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price target for the company. Robert W. Baird raised their target price on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wells Fargo & Company dropped their price target on Inari Medical from $84.00 to $65.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 target price on the stock. Finally, William Blair assumed coverage on shares of Inari Medical in a research report on Thursday, July 25th. They issued an "outperform" rating for the company. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $58.89.

Inari Medical Trading Down 1.8 %

NARI stock traded down $0.90 during mid-day trading on Wednesday, reaching $48.28. 251,630 shares of the stock traded hands, compared to its average volume of 1,000,650. Inari Medical has a 52-week low of $36.73 and a 52-week high of $67.13. The stock's fifty day moving average is $43.51 and its 200-day moving average is $45.96. The company has a market cap of $2.81 billion, a P/E ratio of -37.25 and a beta of 1.00.

Inari Medical (NASDAQ:NARI - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.25). The company had revenue of $145.82 million during the quarter, compared to analyst estimates of $143.96 million. Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%.

Hedge Funds Weigh In On Inari Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. boosted its holdings in Inari Medical by 16.4% during the first quarter. Bessemer Group Inc. now owns 2,439 shares of the company's stock worth $117,000 after purchasing an additional 344 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Inari Medical by 7.7% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company's stock valued at $234,000 after purchasing an additional 348 shares in the last quarter. Arizona State Retirement System lifted its stake in Inari Medical by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company's stock valued at $703,000 after purchasing an additional 358 shares during the last quarter. Covestor Ltd lifted its stake in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company's stock worth $78,000 after buying an additional 376 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after purchasing an additional 435 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company's stock.

Insider Activity

In other Inari Medical news, CFO Mitch C. Hill sold 5,000 shares of the business's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $47.99, for a total transaction of $239,950.00. Following the completion of the sale, the chief financial officer now directly owns 179,600 shares of the company's stock, valued at approximately $8,619,004. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Mitch C. Hill sold 5,000 shares of the company's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $47.99, for a total value of $239,950.00. Following the completion of the sale, the chief financial officer now owns 179,600 shares in the company, valued at approximately $8,619,004. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Mitch C. Hill sold 3,000 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company's stock, valued at $8,105,348. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 88,000 shares of company stock valued at $4,009,340 over the last 90 days. 10.60% of the stock is owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.